Hepatology

Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.

The author of the largest clinical trial for pediatric PFIC to date discusses the various benefit maralixibat provides to disease managementr.

A new review and analysis suggests a combination treatment regimen for children in acute liver failure due to autoimmune hepatitis may help them maintain native liver survival.

Pooled phase 3 data presented at NASPGHAN 2023 support the benefit-risk profile of the IBAT inhibtor in treating the rare liver disease.

Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

Patients aged less than 45 years at NAFLD onset had a higher risk of cancer compared to older age groups, highlighting an association between younger age at NAFLD onset and cancer risk.

The COVID-19 pandemic skyrocketed already high rates of alcohol consumption and related liver disease to unprecedented levels. Addiction specialists and hepatologists are still looking for the best path out.

The presence of NAFLD increased from 25.3% to 29.4% among patients receiving oral menopause hormone therapy.

Investigators suggested an ALT/HDL-C ratio of 15.97 as a screening threshold for identifying NAFLD, noting its increased effectiveness compared to ALT, HDL-C, the aspartate aminotransferase to HDL-C ratio, and the gamma-glutamyl transferase to HDL-C ratio.

Results showed increased liver stiffness measured by vibration-controlled transient elastography was associated with all-cause mortality in patients with NAFLD.

Sarah Wheeler, PharmD, and John Bucheit, PharmD, provide perspective on contemporary trends in screening and management of nonalcoholic fatty liver disease in people with type 2 diabetes.

Increased physical activity and diet quality were associated with a lower risk of all-cause and cardiovascular disease-related mortality among patients with NAFLD.

A study reveals a link between low free thyroxine and fatty liver risk in type 2 diabetes patients, suggesting a gender-specific thyroid-liver interaction.

Investigators developed the identification model based on significantly associated factors of fibrotic NASH and tested it in derivation and validation cohorts, where it identified 89.9% and 81.0% of patients with fibrotic NASH, respectively.

HepaStem, BIV201, and Albutein are late-stage pipeline agents in development for NASH, focusing specifically on decompensated cirrhosis.

Findings showed Fatty Liver Index was predictive of cardiovascular disease mortality among patients with a history of myocardial infarction.

The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV.

The study's findings show an association between NAFLD prevalence, physical activity, and television viewing, with higher levels of physical activity paired with lower levels of television viewing leading to a statistically significantly reduced risk of NAFLD.

Performance metrics of NIS4, the ELF test, and FibroMeter VCTE met prespecified criteria for qualification for regulatory approval in stage 1 of the NIMBLE project's circulating biomarker workstream.

Investigators noted the prevalence of metabolic syndrome was highest among participants with obesity, linking increased BMI to a greater risk of metabolic syndrome and NAFLD severity.

The University of Miami study previews the upcoming phase 3 trial and what the investigative seladelpar may provide patients with primary biliary cholangitis.

The phase 3 seladelpar investigator discusses the current landscape of care available for patients with PBC.

This endocrine case report from Brady Pregerson, MD, features a patients in his mid-70s with a history of hypothyroidism presenting with weeks of nausea, vomiting, and diarrhea without blood but with a 30-pound weight loss. Can you determine the most likely diagnosis?

A number of innovative, virus-targeting agents are under investigation to treat HCV—or even prevent it.

Results from the retrospective cohort study indicated viral eradication with DAAs after liver transplantation improved liver function and patient survival after a long-term follow-up, even in cirrhotic patients.